Clinical Trial Update: Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, and pharmacokinetics of intravitreal pegcetacoplan (APL-2) for neovascular age-related macular degeneration comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Pegcetacoplan (Pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Neovascular Age-Related Macular Degeneration | Phase 1 | Status: COMPLETED | Results posted: 2020-10-06